Co-Authors
This is a "connection" page, showing publications co-authored by Imran Khan and John O'Bryan.
Connection Strength
3.893
-
Identification of the nucleotide-free state as a therapeutic vulnerability for inhibition of selected oncogenic RAS mutants. Cell Rep. 2022 02 08; 38(6):110322.
Score: 0.820
-
Targeting the KRAS a4-a5 allosteric interface inhibits pancreatic cancer tumorigenesis. Small GTPases. 2022 Jan; 13(1):114-127.
Score: 0.777
-
Probing RAS Function with Monobodies. Methods Mol Biol. 2021; 2262:281-302.
Score: 0.759
-
Therapeutic targeting of RAS: New hope for drugging the "undruggable". Biochim Biophys Acta Mol Cell Res. 2020 02; 1867(2):118570.
Score: 0.700
-
Mutations in the a4-a5 allosteric lobe of RAS do not significantly impair RAS signaling or self-association. J Biol Chem. 2022 Nov 02; 102661.
Score: 0.216
-
Targeting the "undruggable" RAS with biologics. Adv Cancer Res. 2022; 153:237-266.
Score: 0.198
-
Inhibition of RAS: proven and potential vulnerabilities. Biochem Soc Trans. 2020 10 30; 48(5):1831-1841.
Score: 0.188
-
Biology, pathology, and therapeutic targeting of RAS. Adv Cancer Res. 2020; 148:69-146.
Score: 0.184
-
Ceramide synthase 6 impacts T-cell allogeneic response and graft-versus-host disease through regulating N-RAS/ERK pathway. Leukemia. 2022 07; 36(7):1907-1915.
Score: 0.052